ArticleBMC infectious diseases2026
Seroprevalence of human T-cell lymphotropic virus and transfusion-transmitted viral hepatitis markers among hemodialysis and thalassemia patients in the South of Iran.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study was designed to determine the seroprevalence of HTLV among multi-transfused patients in the South of Iran.
methodsAll patients with β-thalassemia major and those on regular hemodialysis from the cities of Dashtestan, Bushehr, Genaveh, Tangestan, and Kangan participated in this study. Serum samples were tested for HTLV-I/II antibodies by ELISA, and Western Blot confirmed seropositive samples. Moreover, hepatitis-related markers were assessed using serological assays.
resultsOf 134 thalassemia patients, 6 cases (4.48%, 95% CI: 1.83%-9.91%) were positive for HTLV-I/II antibodies, all of which were confirmed by Western blot as HTLV-1. The hemodialysis patients and the controls were negative for HTLV-I/II antibodies. Of 6 HTLV-1 seropositive thalassemia patients, 4 cases were positive for anti-HCV antibodies (66.7%), and 2 cases were positive for anti-HEV IgG (33.4%). HTLV-1 seropositive thalassemia patients were negative for HBV infection criteria, while 5 of 6 patients (83.33%) had HBsAb in their samples. HTLV-1 seropositivity increased with age and was higher among single patients, female patients, residents of Kangan, patients receiving blood transfusions every two weeks, and Fars patients. Nevertheless, the seroprevalence of HTLV-1 was not statistically associated with marital status, gender distribution, place of residency, frequency of blood transfusion, age, ethnicity, or level of education.
conclusionThis study reports a relatively high seroprevalence of HTLV-1 among patients with β-thalassemia major, highlighting a high risk of HTLV-1 exposure in the thalassemia population. Therefore, an evaluation of introducing HTLV donor screening is recommended to reduce the transmission of HTLV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.